Altman Peter 4

What Happened

• Peter Altman, President, CEO and a director of BioCardia, acquired a total of 1,700 shares of BCDA in two open‑market purchases: 200 shares on 2026-05-19 at a weighted average price of $0.95 ($190) and 1,500 shares on 2026-05-20 at a weighted average price of $0.92 ($1,380). Total cash paid across both trades was approximately $1,570.
• These were purchases (Form 4 code P), which are typically viewed as insider buying rather than routine selling.

Key Details

• Transaction dates and prices:
  • 2026-05-19: 200 shares at weighted avg $0.95 (trades ranged $0.9506–$0.9508) — $190 (footnote F1).
  • 2026-05-20: 1,500 shares at weighted avg $0.92 (trades ranged $0.91–$0.95) — $1,380 (footnote F2).
• Total shares purchased: 1,700; total consideration: ≈ $1,570.
• Shares owned after transaction: Not specified in the provided filing.
• Filing: Form 4 filed 2026-05-21 (covers transactions on May 19 and May 20); filing appears timely (Form 4 is due within two business days).
• Footnotes: Both transactions were executed in multiple trades and reported at weighted average prices; the reporting person offers to provide per‑trade details upon request.

Context

• These were straightforward open‑market purchases (not option exercises, gifts, or awards).
• Purchases by executives are often watched by investors as a sign of confidence, but this summary is factual and does not infer motive.